Endocrine Abstracts

Introduction: The study was a single-center, open label, randomized, head-to-head clinical study to compare the mucosal findings after perform esophagogastroduodenoscopy between two groups before and after use of alendronate only and enterocoating alendronate (5 mg) with calcitriol (0.5 μg) combined drug (Maxmarvil).

Methods: The 33 postmenopausal healthy volunteers, aged 50–70 years (mean age: 58±5 years) without gastrointestinal symptoms and normal baseline endoscopic findings were participated. Esophagogastroduodenoscopy was taken at the time of the baseline and repeated at 2 weeks later after daily intake of Maxmarvil (n=17 subjects) or alendronate (n=16 subjects). Mucosal injury scores were reported by a endoscopist after 2 weeks of each medication.

Results: Esophageal mucosal injuries were developed in two out of 16 subjects with alendronate group only. Gastric mucosal injuries were developed in eight subjects in alendronate group and in four out of 17 subjects with Maxmarvil group, which showed statistically significant differences.

Conclusions: Our study showed that the mucosal damage scores for the alendronate group (total score; 24) are significantly higher than those of scores for the Maxmarvil group (total score; nine) in the esophagus and stomach. Therefore, this study suggests that enterocoating Maxmarvil is more safe on gastrointestinal mucosa than alendronate and may improve the tolerability of osteoporosis medication in clinical practice.

Declaration of interest: The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research project.

Funding: This work was supported, however funding details unavailable.